CHICAGO -- Selumetinib (Koselugo) significantly improved response rates in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas, the phase III KOMET trial ...

I’d like to focus this month’s blog post on a discussion of cutaneous neurofibromas, which are benign tumors that can grow on nerves throughout the body in some individuals with NF1. Typically ...

Scientists have discovered the origin of severely disfiguring masses of cells, called neurofibromas, that gradually develop throughout the skin of patients afflicted with Neurofibromatosis 1 (NF1). In ...

CNW/ - Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in ...

In continuing our discussion from the previous blog regarding how the focus of a clinical trial is determined, I’d like to address the treatment and research of two distinctive features of NF that are ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Mirdametinib is an investigational mitogen-activated ...

The oral granules are contained within capsules that should be opened and administered in smooth yogurt or fruit puree (eg, apple, banana, pear, or strawberry). The Food and Drug Administration (FDA) ...

A study published today in PLOS ONE discovered the origin of severely disfiguring masses of cells, called neurofibromas, that gradually develop throughout the skin of patients afflicted with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Koselugo’s approval was based on data from the phase 3 ...

Cred: SpringWorks Therapeutics. Mirdametinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2. Gomekli is the first medication approved for both adult and pediatric patients with ...

Peripheral nerve sheath tumors, specifically neurofibromas and schwannoma variants, occur both sporadically and in the setting of hereditary conditions, including neurofibromatosis type 1 (NF1), ...